Physician profile
Michael Perkins
NPI 1659666873
$10,170.44
in general payments reported to CMS, 2019-2025
26 companies · $2,814 in 2025
The $2,814 reported for 2025 was more than what 82% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,432 · 2020: $437 · 2021: $1,012 · 2022: $1,363 · 2023: $1,044 · 2024: $2,069 · 2025: $2,814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,921 · Education: $5.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,920.59 |
| Education | $5.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,839.40 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $2,919.98 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Takeda Pharmaceuticals U.S.A., INC. | $416.88 | 2023-2025 | Glassia |
| Regeneron Healthcare Solutions, INC. | $406.37 | 2019-2025 | Dupixent |
| Amgen INC. | $336.35 | 2022-2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $297.40 | 2019-2025 | Ofev |
| Verona Pharma, INC. | $295.88 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $281.36 | 2019-2024 | Tobi Podhaler |
| Viatris Specialty LLC | $239.76 | 2025 | Yupelri |
| Insmed, INC. | $172.78 | 2019-2025 | Arikayce, Brinsupri |
| Sunovion Pharmaceuticals INC. | $165.80 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $147.23 | 2019-2020 | |
| Electromed, INC. | $111.06 | 2024-2025 | Smartvest |
| Jazz Pharmaceuticals INC. | $93.69 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $90.41 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $59.63 | 2019-2023 | |
| Genentech USA, INC. | $55.47 | 2019 | |
| Merck Sharp & Dohme LLC | $54.69 | 2019-2025 | Zerbaxa |
| Actelion Pharmaceuticals US, INC. | $48.12 | 2019 | |
| Advanced Respiratory, INC | $34.68 | 2019 | |
| Shire North American Group INC | $21.42 | 2019 | |
| Lilly USA, LLC | $20.87 | 2025 | Zepbound |
| E.R. Squibb & Sons, L.L.C. | $19.17 | 2019 | |
| Alk-Abello, INC | $18.37 | 2024 | Odactra, Grastek, Ragwitek |
| Circassia INC. | $12.52 | 2019 | |
| Mallinckrodt Enterprises LLC | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Perkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.